Brief: Gilead And Arcus Announce New Data Showing Encouraging Clinical Activity Of Anti-TIGIT Domvanalimab-Containing Regimen As First-Line Treatment For Upper GI Cancers

Arcus Biosciences

06/11/2023 22:04

Nov 6 (Reuters) - Gilead Sciences Inc  GILD.O :
    * GILEAD AND ARCUS ANNOUNCE NEW DATA SHOWING ENCOURAGING
CLINICAL
ACTIVITY OF ANTI-TIGIT DOMVANALIMAB-CONTAINING REGIMEN AS
FIRST-LINE TREATMENT FOR UPPER GI CANCERS
    * GILEAD SCIENCES - PRELIMINARY DATA FROM ARM A1 OF PHASE 2
EDGE-GASTRIC STUDY SHOWED PROMISING ORR AND SIX-MONTH PFS
RESULTS

Source text for Eikon:  ID:nBw39DHX3a 
Further company coverage:  GILD.O 

 ((Reuters.Briefs@thomsonreuters.com))